At CD BioSciences, we specialize in advancing preclinical therapeutic development for human herpesvirus (HHV)-associated malignancies. Oncolytic herpes simplex viruses (oHSVs), particularly genetically engineered strains derived from HSV-1, have emerged as promising agents for the selective targeting and destruction of cancer cells, while sparing healthy tissues. As a key player in HHV research, our oHSV Therapy Solutions provide end-to-end support—from rational vector design to in vivo evaluation—tailored to academic labs, biotech startups, and pharmaceutical innovators aiming to harness this viral immunotherapy platform.
Built on scientific excellence and a virus-specific focus, CD BioSciences delivers customized and scientifically validated workflows that address the unique complexities of working with oncolytic herpesviruses in the context of HHV-driven cancers such as Kaposi's sarcoma (KSHV/HHV-8), Epstein-Barr virus-associated lymphomas (EBV/HHV-4), and others.
Our Service Modules
oHSV Engineering & Validation Support
Genetic engineering of HSV-based oncolytic vectors is a foundational step in therapy development. We offer:
- Custom oHSV Backbone Design: Incorporating tumor selectivity elements, transgene expression cassettes, or immune modulatory genes (e.g., GM-CSF, IL-12).
- Gene Deletion & Mutation Services: UL34, ICP34.5, ICP47, and other deletions to attenuate neurovirulence and enhance tumor specificity.
- Transgene Insertion & Functional Validation: Reporter systems (e.g., GFP, luciferase) and therapeutic payloads validated by qPCR, Western blot, and reporter assays.
- Quality Control: Genome sequencing and restriction fragment analysis for construct verification.
All vectors are produced in accordance with preclinical development standards, with the option of scalable production in Vero or BHK cell lines.
In Vitro & In Vivo Oncolytic Activity Assessment
Demonstrating tumor-specific replication and cytolytic activity is critical for oHSV validation. Our capabilities include:
- In Vitro Cytotoxicity Testing: High-throughput evaluation across HHV-related tumor cell lines, including PEL (primary effusion lymphoma), EBV-positive B-cell lymphomas, and glioblastoma-derived cells.
- Replication Kinetics: Multi-step growth curve profiling in both normal and cancer cells.
- Oncolysis Visualization: Crystal violet staining, time-lapse microscopy, and flow cytometry-based viability assays.
- In Vivo Tumor Models: Subcutaneous, orthotopic, and humanized mouse xenografts. Viral dosing, tumor volume tracking, and survival analysis are fully supported.
- Imaging & Biomarker Tracking: Bioluminescence and fluorescent imaging (IVIS) platforms to monitor virus spread and tumor response.
Immune Profiling & Combination Therapy Evaluation
Modern oHSV strategies seek not only direct oncolysis but also immunogenic modulation of the tumor microenvironment (TME). We help clients:
- Profile Antitumor Immune Activation: Flow cytometry and multiplex cytokine assays to assess CD8+ T cell, NK cell, Treg, and myeloid populations post-treatment.
- Evaluate Immunogenic Cell Death (ICD): DAMPs (e.g., calreticulin, HMGB1) and interferon response pathways assessed via ELISA and RT-qPCR.
- Test Immune Checkpoint Combinations: Synergy testing with anti-PD-1, anti-CTLA-4, or novel immunomodulators.
- Design Rational Combination Regimens: With standard chemotherapeutics (e.g., doxorubicin, paclitaxel) or antiviral sensitizers (e.g., ganciclovir) for dual-action regimens in HHV-associated cancers.
All studies are conducted under tightly controlled and reproducible immune context models.
Biodistribution & Viral Shedding Studies
Safety and regulatory compliance for oHSV products require thorough characterization of viral persistence and dissemination. CD BioSciences offers:
- Biodistribution Analysis: Quantitative PCR, viral plaque assay, and immunohistochemistry in key organs (liver, spleen, brain, lungs) at multiple timepoints.
- Viral Shedding Monitoring: Detection in feces, saliva, and urine via qPCR and infectivity assays.
- Longitudinal Sampling Protocols: Serial blood sampling and viral load tracking over weeks to assess pharmacokinetics.
- Host Anti-Viral Response Evaluation: Seroconversion, neutralizing antibody titers, and antiviral cytokine profiling to inform safety and immune clearance dynamics.
We strictly adhere to the guidelines of ICH S6(R1) and relevant preclinical regulatory frameworks.
Why Choose CD BioSciences?
- Deep HHV Expertise
Our unique specialization in human herpesviruses enables us to tailor oHSV development to virus-specific oncologies, such as EBV-associated NPC or KSHV-associated sarcoma, with scientific precision. - Integrated Workflow
From vector engineering to immune response evaluation, our seamless platforms support iterative optimization and data integration across experimental stages. - State-of-the-Art Infrastructure
Our facilities include BSL-2/BSL-3 virology labs, in vivo imaging systems, and multi-parameter flow cytometry, ensuring robust and reproducible results. - Flexible & Collaborative Engagements
We offer modular service packages, co-development options, and customized experimental design to meet the needs of partners at various stages—from proof-of-concept to IND-enabling studies. - Commitment to Scientific Rigor
All services are backed by domain-trained PhD scientists, strict quality assurance protocols, and transparent reporting formats suited for publication or regulatory submission.
Partner with Us
CD BioSciences is your trusted partner in the development of oHSV-based immunotherapeutics for HHV-associated cancers. Whether you are initiating exploratory studies or seeking IND-ready datasets, our scientifically grounded and technically comprehensive solutions can accelerate your research with precision.
To learn more or discuss your project, please contact us at info@cd-biosci.com or submit a custom inquiry through our website.
References
- Kaufman, H. L., et al. "Oncolytic herpes simplex virus: a promising cancer immunotherapy." Journal of Clinical Investigation 130.10 (2020): 5294–5302. https://doi.org/10.1172/JCI139324
- Bommareddy, P. K., et al. "HSV oncolytic immunotherapy: clinical advances and challenges." Viruses 10.10 (2018): 476. https://doi.org/10.3390/v10090476
- Liu, B. L., et al. "ICP34.5 deleted HSV-1 is a safe and effective oncolytic virus." Nature Medicine 9.3 (2003): 363–369. https://doi.org/10.1038/nm832
- Chiocca, E. A., Rabkin, S. D. "Oncolytic viruses and their application to cancer immunotherapy." Cancer Immunology Research 2.4 (2014): 295–300. https://doi.org/10.1158/2326-6066.CIR-14-0028
- Fukuhara, H., Ino, Y., Todo, T. "Oncolytic virus therapy: a new era of cancer treatment at dawn." Cancer Science 107.10 (2016): 1373–1379. https://doi.org/10.1111/cas.13027